SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " pharma " 700 found 🔀 AI-powered Shuffle
U.S. Supreme Court sides with generic drug maker for severe hypertriglyceridemia agent icosapent ethyl
The decision clears the way for Hikma Pharmaceuticals' sale of icosapent ethyl in the U.S. market.
E-bike safety; lung cancer treatment and prevention; keeping CMA Festival attendees safe; plus other stories with Vanderbilt Health sources
WKRN News 2 interviewed Jeffrey Upperman, MD, FACS, Professor and Chair of the Department of Pediatric Surgery and Surgeon-in-Chief of Monroe Carell Jr. Children’s Hospital at Vanderbilt, about e-bike related injuries following the recent death of a Brentwood High student and a proposal to require safety training before students could ride a bike on a school campus in Williamson County. Fabien Maldonado, MD, MSc,Professor of Medicine and Thoracic Surgery, was on WTVF News Channel 5‘s live studio show, “Openline,” with host Ben Hall, to discuss lung cancer, treatment and prevention. WSMV’s “Today In Nashville” program hosted Vanderbilt LifeFlight paramedic/flight nurse practitioner Tony Smith to talk about safety for the CMA Festival. The New York Times reporter Carl Zimmer interviewed James Crowe, MD, Director of the Vanderbilt Center for Antibody Therapeutics, for a story about the race to find vaccines and treatments as Ebola spreads. The Vanderbilt Health News release about the pilot clinical trial conducted by Vanderbilt Health and Cumberland Pharmaceuticals Inc., that confirms the safety of ifetroban and supports the further development of the drug to prevent cancer metastasis, was picked up by Reuters, Stock Titan,and others. Women We Admire has named Lee Ann Liska, President and Chief Operating Officer, to its list of top women leaders of Nashville for 2026. Radiology Business, Aunt Minnie, Bioengineer, and Imaging Technology News covered the study from Consuelo Wilkins, MD, MSCI, the Mildred Thornton Stahlman Professor in Rural Health and professor of Medicine in the Division of Geriatric Medicine, that found Black and Hispanic people, while known to be far more apt to have dementia, are significantly less apt than other racial and ethnic groups to show Alzheimer’s pathology on brain scans. STAT News interviewed Deva Sharma, MD, Transfusion Medicine & Hematology-Oncology, for a story about more patients requesting unvaccinated blood and what it means for the medical system at large. Yahoo! Health reporter Korin Miller interviewed Gitanjali Srivastava, MD, Director of Obesity Medicine, for a story about how semaglutide and tirzepatide compare. William Schaffner, MD, Professor of Preventive Medicine, was quoted by several news outlets about public health issues, including: NBC News (new COVID vaccinations); Medscape (pneumonia and sepsis); and CNN (protection from contagious viruses). Shelbyville Times-Gazette is repurposing Jessica Pasley’s July 2025 Vanderbilt Health News story on tick-borne illnesses as a front-page story.
UNT Health Fort Worth’s new pharmaceutical sciences program comes at ‘critical time’ for region
Starting this fall, UNT Health Fort Worth will offer a new pharmaceutical sciences PhD program — the first of its kind in North Texas. The school said the new program could help address workforce needs as the life sciences and research and development industries continue to grow in the region.
UNT Health Fort Worth’s new pharmaceutical sciences program comes at ‘critical time’ for region
Starting this fall, UNT Health Fort Worth will offer a new pharmaceutical sciences PhD program — the first of its kind in North Texas. The school said the new program could help address workforce needs as the life sciences and research and development industries continue to grow in the region.
UNT Health Fort Worth’s new pharmaceutical sciences program comes at ‘critical time’ for region
Starting this fall, UNT Health Fort Worth will offer a new pharmaceutical sciences PhD program — the first of its kind in North Texas. The school said the new program could help address workforce needs as the life sciences and research and development industries continue to grow in the region.
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable pharmaceutical company in the world.
Phone calls from a pharmacist could help people achieve healthy cholesterol, say researchers
Regular follow-up calls from a pharmacist can help people lower their "bad" (LDL) cholesterol by reminding them to take their medication, based on research presented at the British Cardiovascular Society ...
PA program launches Doctor of Medical Science degree - News
New degree program aims to advance healthcare leadership in state, region The Physician Assistant program in the College of Pharmacy… More on this post
UW Health rolls out next-day home delivery for prescriptions for patients in Dane County
For patients in Dane County, UW Health can now deliver prescriptions to the patient’s home the day after the order is placed - for free, Aaron Webb, the director of ambulatory care pharmacy services at UW Health said Tuesday.
Deep Science Ventures and MDC partner to accelerate brain treatments
New collaboration aims to break barriers in brain‑targeted drug discovery
Servier to buy Edgewise's muscular dystrophy business for $2.65bn
Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at up to $2.65bn.
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
/PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has entered into an agreement to...
At Ramapo DNA lab, genealogy meets science to solve cold cases
Dozens of times over four years, researchers have hit on matches that bring closure to families and free the wrongfully convicted
Opinion: Untying the hands of Alaska’s most accessible healthcare providers
Legislation giving pharmacists new prescribing and patient-care authority is now in the hands of the governor.
After Gaza, Israel is now causing the West Bank health system to collapse
Most Medications Are Missing From Public Pharmacies, and Many Patients Cannot Afford to Buy Them on the Private Market. Israel's Seizure of Customs Revenues Has Significantly Deepened the Palestinian Health Ministry's Debt, and It Warns: Soon We Will No Longer Be Able to Provide Essential Health Services
How Nigeria’s ‘algorithmic apothecary’ fuels a surge in risky herbal cures
Unverified herbal remedies promoted on social media are driving rising health risks and delayed treatment in Nigeria.
Power of Two: Health plans becoming fiduciary litigation target
A new wave of litigation is targeting health and welfare plans, particularly voluntary benefits, pharmacy benefit managers, and fee structures embedded in vendor arrangements.
Longevity science picks up steam in pharma
Fueled by multi-billion-dollar valuations and a deeper understanding of aging biology, the field is rapidly moving past the hype and into the clinic.
ETSU grad earns prestigious public health pharmacy award
ETSU Bill Gatton College of Pharmacy graduate Christina Tarasidis Pitchford was one of just 85 nationwide to receive a prestigious national award.
Polish scientists and students rally in campaign for 3% funding target
Polish scientists and students have been flooding social media with calls on the government to raise research and development spending as part of 3% for Science, 100% for Poland, a campaign born earlier this month out of frustration with chronic underfunding in the academic sector. On May 27, thousands took the slogan on to the streets.The EU has been trying to convince member states to raise their R&D expenditures to 3% of GDP for more than two decades, but the idea has never gained traction in capitals. Finance ministers were too busy plugging budget holes created in the aftermath of the 2008 crisis, then the Covid pandemic, the war in Ukraine, and now the war in Iran.Critics say that countries missed or ignored the target because it is voluntary, but also because research communities have rarely raised their voice to put pressure on national governments. The European Commission hopes to make the target legally binding in the upcoming European Research Area Act, an EU-wide regulation that should be announced by the end of the year. Academia in Poland has been faced with a funding crisis for years, often leaving its members with no other choice but to work abroad in order to access better resources, or leave the sector altogether in the hope of earning a decent living. The risk, in the long-term, is that brain drain stifles local innovation capacity and technological competitiveness.In just a few weeks, the movement rallied nationwide support, including from major academic bodies and trade unions such as the Conference of Rectors of Academic Schools in Poland and the Presidium of the Polish Academy of Sciences. Its public petition collected more than 23,000 signatures. On May 27, it formed the first large protest for science in Poland, gathering thousands of people in front of the parliament building in Warsaw.Ilona Uryga-Bugajska, representative of the Marie Curie Alumni Association Poland Chapter, was there. “The protest was peaceful, with no incidents reported, and the entire event took place in a respectful and calm atmosphere,” she said. Banners she saw in the crowd carried slogans such as “A little longer and I’ll be teaching in a supermarket,” “National culture, starvation salary,” “Stop the destruction of science,” “Passion will not pay the rent,” “Without action, don’t expect a better future,” and “Pull science out of the hole.” She also observed a strong presence of young researchers, who are on the frontline of Poland’s academic crisis.“Academics are usually people who prefer discussion, analysis, dialogue and compromise. We are not a group that protests easily,” said Katarzyna Marzec, professor at the Faculty of Pharmacy of the Jagiellonian University Medical College and AGH University of Krakow, who also took part. “But many of us feel that we have been pushed against the wall.”Aleksandra Rutkowska, translational neuroscientist and research group leader at the Medical University of Gdańsk, agreed. “Frustration in the scientific community is very high,” she said. “Science is often used politically as a symbol of innovation and modernity, but the everyday reality inside many institutions is much more difficult. There is a large gap between the public narrative and the actual condition of the sector.”Maria Wiktoria Górna, head of the structural biology group at the University of Warsaw and one of the organisers of the movement, told Science|Business that the campaign would continue without proven results. This might involve another strike in the autumn, she said. “Empty promises are not enough by now.”Campaign demandsAccording to Uryga-Bugajska, the organisers officially presented their demands and concerns to representatives of the government present at the event. These included Marek Gzik, deputy minister of science and higher education, and Karolina Zioło-Pużuk, secretary of state of that same ministry.The headline demand, for the government to increase national spending on R&D to 3% of GDP by 2030, should be within Poland’s economic capacity, Rutkowska said. “The real question is whether there is genuine long-term political commitment to treating science as a strategic priority rather than a slogan.”In 2024, R&D expenditure in Poland stood at 1.41% of GDP, which is slightly above the average for central and eastern Europe, with countries such as Czechia recording 1.82%, Hungary 1.31% and Romania 0.46%. However, it falls noticeably short of the EU average of 2.24%, which just a handful of countries exceed, including Germany, Belgium and Sweden.Campaigners are also asking for fair wages for scientific staff, including PhD stipends and junior academic salaries, which are widely considered uncompetitive. Starting doctoral scholarships amount to some €843 gross per month, when the statutory minimum wage stands at €1,135. By pushing early-career researchers out of Poland, growing precarity has caused a generational gap in the academic workforce, with just 25% of lecturers aged under 40. In this context, the movement fears that scientific careers could soon be accessible to a privileged minority only.Grzegorz Spólnik is a case in point. After 15 years working in mass spectrometry at the Polish Academy of Sciences, he decided to leave partly “to earn enough money to live a normal life,” he said. “At that time, my earnings were similar to those of people working in grocery shops, and the work-life balance is something that does not exist in science, or is very hard to achieve.”Now a senior field service engineer for Polish laboratory equipment supplier Bioanalytic, he would consider going back to research, “but never in the public sector, maybe some start-up or a big private company with ambitious R&D.”The campaigners want to see more support for basic research and have called for €236 million to be added to the budget of the National Science Centre (NCN) in 2027 so that the average grant application success rate does not fall below 25%.“At the protest, there was a banner I particularly liked: ‘NCN is not a lottery.’ Unfortunately, for many researchers, it increasingly feels exactly like one,” Marzec said. “Personally, I am one of the lucky ones. I work at two of the strongest institutions in the country, where the research standards are very high. I know that in many other institutions, the situation is much worse and obtaining funding for research at an early-career stage is becoming nearly impossible.”Rutkowska also considers herself fortunate. After studying abroad and holding a postdoctoral position, she returned to Poland, where her pay was supported through an NCN-funded project linked to the Marie Skłodowska-Curie Actions. “This also made me very aware that good research conditions in Poland often depend on external competitive funding rather than on stable support from the system itself,” she said.Long-term strategyBeyond the lack of funds for both salaries and grants, scientists believe that the issue is structural. “The biggest problem at the moment is the complete lack of a clear long-term strategy for the development of science and research from the current government,” Marzec said. “Everything ends with declarations and promises that are never truly followed by concrete actions or structural reforms.”Rutkowska agreed, citing a lack of infrastructure, continuity and long-term institutional support.“Running a research group in Poland often means functioning as an entire institution at once,” she said. “I am a principal investigator, a mentor, a recruiter, a project administrator and, when needed, still someone who returns to the lab bench to help with experiments,” she went on. “This creates a large hidden workload that takes time and energy away from actual science. At times, it feels as though scientists are no longer expecting extra help; we simply hope the system will stop creating additional obstacles that make research unnecessarily difficult.”Related articlesStrategic thinking: Germany funds joint research with Poland and FrancePoland to transfer €30M of regional funds to boost Horizon Europe participationPoland is funding fewer basic research grants as high inflation hitsIn short, “academics are expected to teach, publish papers, apply for grants and conduct high-quality research, while funding and salaries remain very limited,” said Uryga-Bugajska, who returned to her home country after 13 years in the UK.According to Marzec, another issue is the way that research institutions are evaluated. Previously, this took place every four years, with a clear differentiation between stronger and weaker institutions. “The current government, perhaps to avoid political backlash, effectively concluded that everyone is doing well, so in practice no meaningful evaluation took place,” she said.But in her view, “some form of serious assessment is necessary” to ensure the excellence and international competitiveness of Polish institutions, and to determine how to best use public resources and where institutional structures need reform. “Some institutions may need to rethink hiring practices in order to attract ambitious young researchers who are capable of obtaining competitive grants and building internationally visible research groups.” Rutkowska has already had to adapt. “When hiring PhD students, I often have to combine different funding sources creatively to make positions attractive enough for talented people to stay in science,” she said. “Many young researchers do not see a stable future in academia in Poland, and that is deeply worrying.”
Polish scientists and students rally in campaign for better conditions
Polish scientists and students have been flooding social media with calls on the government to raise research and development spending as part of 3% for Science, 100% for Poland, a campaign born earlier this month out of frustration with chronic underfunding in the academic sector. On May 27, thousands took the slogan on to the streets.The EU has been trying to convince member states to raise their R&D expenditures to 3% of GDP for more than two decades, but the idea has never gained traction in capitals. Finance ministers were too busy plugging budget holes created in the aftermath of the 2008 crisis, then the Covid pandemic, the war in Ukraine, and now the war in Iran.Critics say that countries missed or ignored the target because it is voluntary, but also because research communities have rarely raised their voice to put pressure on national governments. The European Commission hopes to make the target legally binding in the upcoming European Research Area Act, an EU-wide regulation that should be announced by the end of the year. Academia in Poland has been faced with a funding crisis for years, often leaving its members with no other choice but to work abroad in order to access better resources, or leave the sector altogether in the hope of earning a decent living. The risk, in the long-term, is that brain drain stifles local innovation capacity and technological competitiveness.In just a few weeks, the movement rallied nationwide support, including from major academic bodies and trade unions such as the Conference of Rectors of Academic Schools in Poland and the Presidium of the Polish Academy of Sciences. Its public petition collected more than 23,000 signatures. On May 27, it formed the first large protest for science in Poland, gathering thousands of people in front of the parliament building in Warsaw.Ilona Uryga-Bugajska, representative of the Marie Curie Alumni Association Poland Chapter, was there. “The protest was peaceful, with no incidents reported, and the entire event took place in a respectful and calm atmosphere,” she said. Banners she saw in the crowd carried slogans such as “A little longer and I’ll be teaching in a supermarket,” “National culture, starvation salary,” “Stop the destruction of science,” “Passion will not pay the rent,” “Without action, don’t expect a better future,” and “Pull science out of the hole.” She also observed a strong presence of young researchers, who are on the frontline of Poland’s academic crisis.“Academics are usually people who prefer discussion, analysis, dialogue and compromise. We are not a group that protests easily,” said Katarzyna Marzec, professor at the Faculty of Pharmacy of the Jagiellonian University Medical College and AGH University of Krakow, who also took part. “But many of us feel that we have been pushed against the wall.”Aleksandra Rutkowska, translational neuroscientist and research group leader at the Medical University of Gdańsk, agreed. “Frustration in the scientific community is very high,” she said. “Science is often used politically as a symbol of innovation and modernity, but the everyday reality inside many institutions is much more difficult. There is a large gap between the public narrative and the actual condition of the sector.”Maria Wiktoria Górna, head of the structural biology group at the University of Warsaw and one of the organisers of the movement, told Science|Business that the campaign would continue without proven results. This might involve another strike in the autumn, she said. “Empty promises are not enough by now.”Campaign demandsAccording to Uryga-Bugajska, the organisers officially presented their demands and concerns to representatives of the government present at the event. These included Marek Gzik, deputy minister of science and higher education, and Karolina Zioło-Pużuk, secretary of state of that same ministry.The headline demand, for the government to increase national spending on R&D to 3% of GDP by 2030, should be within Poland’s economic capacity, Rutkowska said. “The real question is whether there is genuine long-term political commitment to treating science as a strategic priority rather than a slogan.”In 2024, R&D expenditure in Poland stood at 1.41% of GDP, which is slightly above the average for central and eastern Europe, with countries such as Czechia recording 1.82%, Hungary 1.31% and Romania 0.46%. However, it falls noticeably short of the EU average of 2.24%, which just a handful of countries exceed, including Germany, Belgium and Sweden.Campaigners are also asking for fair wages for scientific staff, including PhD stipends and junior academic salaries, which are widely considered uncompetitive. Starting doctoral scholarships amount to some €843 gross per month, when the statutory minimum wage stands at €1,135. By pushing early-career researchers out of Poland, growing precarity has caused a generational gap in the academic workforce, with just 25% of lecturers aged under 40. In this context, the movement fears that scientific careers could soon be accessible to a privileged minority only.Grzegorz Spólnik is a case in point. After 15 years working in mass spectrometry at the Polish Academy of Sciences, he decided to leave partly “to earn enough money to live a normal life,” he said. “At that time, my earnings were similar to those of people working in grocery shops, and the work-life balance is something that does not exist in science, or is very hard to achieve.”Now a senior field service engineer for Polish laboratory equipment supplier Bioanalytic, he would consider going back to research, “but never in the public sector, maybe some start-up or a big private company with ambitious R&D.”The campaigners want to see more support for basic research and have called for €236 million to be added to the budget of the National Science Centre (NCN) in 2027 so that the average grant application success rate does not fall below 25%.“At the protest, there was a banner I particularly liked: ‘NCN is not a lottery.’ Unfortunately, for many researchers, it increasingly feels exactly like one,” Marzec said. “Personally, I am one of the lucky ones. I work at two of the strongest institutions in the country, where the research standards are very high. I know that in many other institutions, the situation is much worse and obtaining funding for research at an early-career stage is becoming nearly impossible.”Rutkowska also considers herself fortunate. After studying abroad and holding a postdoctoral position, she returned to Poland, where her pay was supported through an NCN-funded project linked to the Marie Skłodowska-Curie Actions. “This also made me very aware that good research conditions in Poland often depend on external competitive funding rather than on stable support from the system itself,” she said.Long-term strategyBeyond the lack of funds for both salaries and grants, scientists believe that the issue is structural. “The biggest problem at the moment is the complete lack of a clear long-term strategy for the development of science and research from the current government,” Marzec said. “Everything ends with declarations and promises that are never truly followed by concrete actions or structural reforms.”Rutkowska agreed, citing a lack of infrastructure, continuity and long-term institutional support.“Running a research group in Poland often means functioning as an entire institution at once,” she said. “I am a principal investigator, a mentor, a recruiter, a project administrator and, when needed, still someone who returns to the lab bench to help with experiments,” she went on. “This creates a large hidden workload that takes time and energy away from actual science. At times, it feels as though scientists are no longer expecting extra help; we simply hope the system will stop creating additional obstacles that make research unnecessarily difficult.”Related articlesStrategic thinking: Germany funds joint research with Poland and FrancePoland to transfer €30M of regional funds to boost Horizon Europe participationPoland is funding fewer basic research grants as high inflation hitsIn short, “academics are expected to teach, publish papers, apply for grants and conduct high-quality research, while funding and salaries remain very limited,” said Uryga-Bugajska, who returned to her home country after 13 years in the UK.According to Marzec, another issue is the way that research institutions are evaluated. Previously, this took place every four years, with a clear differentiation between stronger and weaker institutions. “The current government, perhaps to avoid political backlash, effectively concluded that everyone is doing well, so in practice no meaningful evaluation took place,” she said.But in her view, “some form of serious assessment is necessary” to ensure the excellence and international competitiveness of Polish institutions, and to determine how to best use public resources and where institutional structures need reform. “Some institutions may need to rethink hiring practices in order to attract ambitious young researchers who are capable of obtaining competitive grants and building internationally visible research groups.” Rutkowska has already had to adapt. “When hiring PhD students, I often have to combine different funding sources creatively to make positions attractive enough for talented people to stay in science,” she said. “Many young researchers do not see a stable future in academia in Poland, and that is deeply worrying.”
An update on Amazon Health Services leadership
Doug Herrington and Neil Lindsay welcome Dr. Roy Schoenberg as new head of healthcare business.
Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
CVS sues Tennessee in latest challenge to state PBM laws
The same day that Tennessee Gov. Bill Lee signed a bill that would force pharmacy benefit managers to divest from retail pharmacies, CVS Health filed a lawsuit to block its implementation.
TTUHSC’s Klein Selected to Leadership Role by the Texas Pharmacy Association
The Texas Pharmacy Association announced (May 19) the appointment of Mary Klein, Pharm.D., as assistant vice president of Strategic Initiatives and Practice Innovation.
Three Monarchs Earn Prestigious National Science Foundation Graduate Research Fellowships
By Robyn Sidersky Three recent Old Dominion University graduates are preparing to tackle some of society’s biggest scientific challenges, from developing sustainable pharmaceuticals to restoring wetlands and advancing regenerative medicine, with help from one of the nation’s most prestigious graduate fellowships.
Croma Skincare – Where Science Meets Skin
LEOBENDORF, Austria, May 26, 2026--With Croma Skincare, Austrian family-owned company Croma Pharma translates decades of expertise in aesthetic medicine into a modern skincare line designed for everyday results. Rather than following short-lived trends, Croma focuses on scientifically proven ingredients and pharmaceutical-grade formulations that deliver visible performance while fitting seamlessly into daily routines.
Lantheus weighs potential sale with $7B valuation
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
Sun Pharma, Coforge: Indian businesses go shopping abroad as growth slows at home
India Inc spent $18bn on global buyouts in 2025 and the deal value could cross $15bn in the first half of 2026.
CVS Health (CVS) Price Target Boosted by $8 at Mizuho
With an annual dividend yield of 2.84%, CVS Health Corporation (NYSE:CVS) is included among the 12 Best Dividend Stocks to Invest in According to Hedge Funds. America’s leading health solutions company, CVS Health Corporation (NYSE:CVS) provides advanced health care from pharmacy services and health plans to health and wellness. On May 20, Mizuho bumped up its price […]
Illinois healthcare bills at stake as spring session enters final week
The biggest battles in healthcare legislation may involve Big Pharma, but several other health bills are at the make-or-break stage this coming week in Springfield.
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
Anavex Life Sciences Corp. (“Anavex” or the “Company”)(Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) disorders, today announced it received anexpected delinquency notification letter (the “Notice”) from the Listing QualificationsDepartment of The Nasdaq Stock Market LLC (“Nasdaq”) on May 20, 2026.
World Health Assembly endorses resolution on precision medicine
At the Seventy-ninth World Health Assembly, Member States endorsed a new resolution on Precision medicine: a path towards targeted, personalized and equitable care, taking an important step towards advancing precision medicine as part of efforts to strengthen equitable, effective and sustainable health systems. Precision medicine refers to the use of clinical, molecular, genomic and other health data to inform prevention, diagnosis and treatment, taking into account variability while applying appropriate ethical and legal safeguards. When integrated responsibly into health systems, precision approaches can improve outcomes across different disease areas and across the life course – from cancer and rare diseases to infectious diseases, maternal, newborn and child health, mental health and noncommunicable diseases. The resolution reflects rapid advances in genomics, diagnostics, data science and digital health, alongside widening global inequities in access to these innovations. Many populations – particularly in low- and middle-income countries – remain underrepresented in data and research, limiting the public health impact of precision medicine and risking the widening of health disparities if action is not taken now. "Precision medicine is not an aspirational idea for health delivery in the future – it is already transforming lives across the world. But its benefits remain out of reach for too many and the research driving progress is concentrated in high income countries. This WHA resolution gives global health leaders, ministries of health, and WHO a clear mandate: to act. From infant screening to setting up genomic databases WHO will work with countries to bring about the power of these innovations." Dr Meg Doherty, Director Science for HealthThrough the resolution, Member States commit to developing and strengthening national policies, infrastructure, workforce capacity and governance frameworks to support the safe, ethical and equitable integration of precision medicine into health systems, aligned with universal health coverage. This includes promoting affordability, ensuring inclusive research and data systems, strengthening regulation and data governance, and fostering collaboration across sectors and regions.WHO is requested to provide technical and normative support, review and coordinate existing guidance, facilitate global and regional collaboration, and develop a Global Strategy on Precision Medicine to guide equitable and context‑appropriate implementation. WHO stands ready to support Member States through tools such as a country maturity model for countries to self-assess capacity in implementing precision medicine depending on their context. In the immediate term WHO will map all existing guidance and frameworks and host extensive consultations with interest holders globally.By placing equity, inclusion and public value at the centre of precision medicine, the resolution reinforces WHO’s commitment to ensuring that scientific advances benefit all people, everywhere, and that no one is left behind in the next era of health innovation."By uniting people-centered healthcare with innovation, precision medicine has the potential to transform lives. This resolution helps ensure those advances serve the shared goal of health for all." Dr Sylvie Briand, Chief Scientist For further information please visit the Health Topic: Genomics
The Science Behind the Quest for a Non-Peptide Oral Weight Loss Drug
Not only does it have a tongue-twisting name, “orforglipron” has a complex molecular structure that made its synthesis very challenging. A massive effort by chemists at the Eli Lilly pharmaceutical
College of Pharmacy & Health Sciences to host statewide symposium - News
The Campbell University College of Pharmacy & Health Sciences will welcome healthcare leaders, educators, pharmacists and students from across North… More on this post
Health Care Roundup: Market Talk
Find insight on AstraZeneca, Sino Biopharmaceutical, ConvaTec and more in the latest Market Talks covering the Health Care sector.
Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call
NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on devel...
Wellgistics Health and Datavault AI to Form DelivMeds AI via PharmacyChain™ License Expansion and Acquisitions of QOLPOM Biometric Health Data and Drone Logistics IP and Majority of Tollo Health
Formation of DelivMeds AI, Inc. (ticker reserved: NASDAQ:MEDS), with an expected approximate combined asset value of $4 billion, is subject to…...
Supreme Court deals blow to Big Pharma
Presented by Coalition to Strengthen America’s Healthcare{beacon} View Online Health Care Health Care PRESENTED BY The Big Story Supreme Court deals blow to pharma challenge …
Former medical director of Ames health spa faces more sanctions
The former medical director of an Ames health spa is facing sanctions from a second state licensing board.
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
/PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc....
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
UNMC, UNK celebrate opening of rural health education complex
Kearney facilities expand UNMC offerings in medicine, pharmacy, public health, nursing and allied health.
BrightSpring Health Services (BTSG) Is Up 10.3% After Raising 2026 Revenue Guidance And Q1 Beat – Has The Bull Case Changed?
In early May 2026, BrightSpring Health Services reported first-quarter results showing revenue of US$3.61 billion and net income of US$148.77 million, and also raised its full-year 2026 earnings guidance to expected revenues of US$14.73 billion to US$15.23 billion. The combination of outperformance in specialty pharmacy and infusion services, efficiency gains from automation, and successful home health integrations is reshaping how investors view BrightSpring’s earnings power and growth...
Supreme Court preserves access to widely used abortion pill, while lawsuit plays out
The court’s order allows women seeking abortions to continue obtaining the drug, mifepristone, at pharmacies or through the mail, without an in-person visit to a doctor. Access is likely to remain uninterrupted at least until into next year as the case plays out, including a potential appeal to the high court.
Wi-Fi confab, NorthPark playhouses in this week's business datebook
This week’s events in North Texas include earnings from major companies, including Eagle Materials, Lantern Pharma and GameSquare Holdings.
TransCelerate Research Examines the Role of Digital Health Technologies in Patient Safety, Published in DIA's Therapeutic Innovation & Regulatory Science
/PRNewswire/ -- TransCelerate BioPharma (TransCelerate), a nonprofit organization dedicated to improving the health of people around the world by accelerating...
KFF Poll Finds That Most Adults Lack Confidence in Key Health Agencies to Act Independently — The Monitor
KFF’s latest Health Tracking Poll finds that confidence in the independence of key government health agencies overseeing food and drug safety and public health is low among the public and across partisans. Most of the public also share a distrust of agriculture, food, and pharmaceutical companies to act in the public’s best interest, compared with doctors and health care providers who are much more trusted among the public.
CVS Health® and WGU launch online pre-pharmacy degree program for future pharmacists nationwide
New program helps reduce financial barriers to higher education while building a stronger, more robust pharmacy workforce
Precigen Reports First Quarter 2026 Financial Results and Business Updates
Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients, today announced first quarter 2026 financial results and business updates.
Celebrating Healthcare Week at UConn Health- Pharmacy
WFSB and Dr. Andy surprised the UConn Health Pharmacy team as part of Healthcare Week celebrations.
Azitra, Inc. Announces Q1 2026 Results and Provides Business Updates
/PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative...
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor (MCR) system, today announced financial results for its fiscal third quarter ended March 31, 2026, and provided a business update.
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif., May 13, 2026--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended March 31, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates.
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
MARSEILLE, France, May 13, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its business update and consolidated financial results for the quarter ending March 31, 2026.
The Best Over-the-Counter Products of 2026, According to U.S. News & World Report
Hundreds of pharmacists and dermatologists were surveyed to discover the top finds.
Health Care Roundup: Market Talk
Find insight on the deal between Hengrui Pharmaceuticals and Bristol Myers Squibb and more in the latest Market Talks covering the health care sector.
Commencement 2026: Pharmacy graduate combines passion for care with business acumen to provide total patient support
KINGSTON, R.I. — May 12, 2026 — For Alayna Ballavia, who will graduate from the University of Rhode Island with two advanced degrees—including a Pharm.D. from the College of Pharmacy—some of the most meaningful lessons she learned about pharmacy, healthcare, and life in general happened far beyond the classroom. During two international medical missions in […]
Bayer Profit Up On Seed Business But Glyphosate Sales Struggle
German agrichemical and pharmaceutical giant Bayer reported a bump in first-quarter profit on Tuesday, driven by its agricultural business, even as sales of controversial glyphosate-based weedkillers struggled.
Scripta Insights and Quantum Health Announce Strategic Partnership for Pharmacy Cost Reduction
/PRNewswire/ -- Scripta Insights, the Rx navigation company™ and Quantum Health, the leading healthcare navigation company, today announced a strategic...
Eli Lilly shoots for health in new Caitlin Clark ad campaign
Flashy three pointers; top athletes playing under the lights; cameras focusing in on our celebrity making a game-winning shot—all elements you’d typically associate with a Big Pharma ad featuring a | Flashy three pointers; top athletes playing under the lights; cameras focusing in on our celebrity making a game-winning shot—all elements you’d typically associate with a Big Pharma ad featuring a major athletic celebrity. Not for Eli Lilly though.
Reach Out and Read 5K brings together health professional students
Hosted by the School of Pharmacy Kappa Psi Beta Eta, the Mountaineer mascot recently kicked off the Reach Out and Read 5K at the Student Rec Center. The event collected nearly 90 books to be distributed to pediatric patients during their checkups.
Avalere Health expands to Japan with a full-service Advisory, Medical, and Marketing offering, led by industry veteran Junji Yokokawa
Avalere Health, a global strategic partner for the healthcare industry, today announces the launch of its Japan office. The move marks a significant expansion of Avalere Health's global footprint, and the launch of a new strategic offering is designed to support Japanese biopharmaceutical companies end-to-end across the product lifecycle.
CVS Health Q1 Earnings Call Highlights
CVS Health (NYSE:CVS) raised its full-year 2026 adjusted earnings outlook after reporting stronger first-quarter results, with management citing improved performance at Aetna, continued execution at Caremark and resilient pharmacy operations. On the company’s first-quarter earnings call, David Joyn
College of Pharmacy & Health Sciences confers 206 degrees - News
The Campbell University College of Pharmacy & Health Sciences celebrated the accomplishments of the Class of 2026 during its Spring… More on this post
College of Pharmacy & Health Sciences confers 206 degrees - News
The Campbell University College of Pharmacy & Health Sciences celebrated the accomplishments of the Class of 2026 during its Spring… More on this post
Germany’s Healthcare Reforms Herald More Pain for Big Pharma
Donald Trump’s push to bring down drug prices in the US has rattled the world’s leading pharmaceutical companies. Now, they’re confronting a new menace as Germany seeks to plug a ballooning deficit in its public health-insurance funds.
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Advancing next-generation γδ T cell engager platform with initial animal data expected in 2026Reported glioblastoma (GBM) data showing ~97% improvement in progression-free survival vs. standard-of-care; updated median overall survival (mOS) data to be presented at ASCO 2026Hosting R&D Day on May 21, 2026 in New York City NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and γδ
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the appointment of Nelson Azoulay as Chief Business Officer. Mr. Azoulay joins Pyxis Oncology with more than 15 years of experience in corporate strategy, business development, and value-creating transactions across the biopharma industry, including deep antibody-drug conjugate (ADC) experience. In his role,
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
/PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and...
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Successfully dosed all four planned healthy volunteer SAD cohorts of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Preliminary pharmacokinetic (PK) modeling from HEADLINE trial supports ABS-201's targeted dosing interval Initiated dosing of first MAD cohort of AGA participants of ongoing ABS-201™ HEADLINE trial Expanding prolactin program portfolio with addition of ABS-202 to internal pipeline VANCOUVER, Wash. and NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- A
UToledo Unveils Online Master’s Degree Focused on Health Outcomes and Analytics
The 100% online graduate program equips healthcare professionals with cutting-edge, in-demand analytical skills.
Anglonordic Life Science 2026: A focus on execution
The latest Anglonordic Life Science Conference on 23rd April exhibited a cautious optimism.
CVS blows past estimates, hikes outlook as insurance business outperforms
All of the health-care giant's business segments, including its insurer Aetna, its retail pharmacy and health services unit, surpassed expectations.
White House says Trump's deals with pharmaceutical companies offer billions in savings
WASHINGTON (AP) — White House economists estimate that President Donald Trump’s deals with pharmaceutical companies to drop some of their U.S. prescription drug prices to what they charge in other countries could save $529 billion over the next 10 years. The analysis obtained by The Associated Press includes the first economy-wide projections behind a policy at the core of Trump’s pitch to voters going into November’s midterm elections for control of the House and Senate.
U.S. Embassy Supports Tunisian Business Delegation at 2026 SelectUSA Investment Summit - U.S. Embassy in Tunisia
U.S. EMBASSY SUPPORTS TUNISIAN BUSINESS DELEGATION AT 2026 SELECTUSA INVESTMENT SUMMIT The SelectUSA Investment Summit is the premier U.S. investment event, connecting thousands of investors, companies, economic development organizations, and industry experts to make deals happen. Media Note TUNIS, May 5, 2026 – U.S. Embassy Tunis is pleased to support a delegation of 11 Tunisian companies traveling to the United States to participate in the 2026 SelectUSA Investment Summit at National Harbor, Maryland, May 3-6, 2026. The Summit is an opportunity for these dynamic entrepreneurs to establish new connections and explore business and investment opportunities in the United States. This year, three Tunisian women entrepreneurs and members of the delegation representing Spiraw and Sotetel were accepted into the Select Global Women in Tech year-long mentoring program which will kick off at the summit. Since 2022, more than 50 Tunisian entrepreneurs in fields ranging from e-gaming, robotics, software engineering, coding, online fashion, and green tech have participated in SelectUSA Investment Summits, where they have taken their businesses to the next level. Hosted by the U.S. Department of Commerce, the SelectUSA Investment Summit is a one-stop shop for companies considering expanding to the United States and provides economic development organizations (EDOs) with the opportunity to meet directly with international companies to facilitate investment deals. Since inception, the SelectUSA Investment Summit has attracted tens of thousands of companies and economic development representatives, generating over $250 billion in new investment projects that support more than 125,000 jobs across the United States and its territories. The previous SelectUSA Investment Summit saw record-breaking numbers with more than 5,500 participants, including EDOs from 54 U.S. states and territories and over 2,700 business investors from 100+ countries, including Tunisia. The following Tunisian businesses will take part in this year’s SelectUSA delegation: AquaDeep – Revolutionizes aquaculture with AI-powered monitoring solutions, including a real-time larva counting system and a SaaS platform for environmental monitoring. The company is expanding operations across Tunisia, Europe, Africa, and the United States. Bouraoui Group – Specializes in event venues, hospitality experiences, innovative real estate development, and technology driven customer solutions. The business develops experience- focused and tech enabled lifestyle destinations that combine entertainment, culture, retail, and smart services, and is seeking international partners to co-develop hospitality, PropTech, smart retail, and experiential digital projects. Digital Cook – Builds HR and recruitment software solutions, including HRMS, ATS, and custom tools that streamline hiring, employee management, and talent development. It provides custom software, system integration, and scalable HR platforms for SMEs, large enterprises, and recruitment agencies seeking efficient, user-friendly ways to manage their workforce and improve recruitment. El Kanaouet – Provides high-quality and low-cost hydraulic infrastructure for the supply and distribution of drinking water. The company manufactures prestressed concrete structures based on current technological developments in the field and trends in integrated and digitalized management. El Kanaouet aims to enter the U.S. market with its production of centrifugal prestressed concrete pipes and other technical products and services. Fluoink Nanotechnologies – A deep‑tech startup developing next‑generation antimicrobial additives for paints, coatings, and industrial materials, enabling everyday surfaces to act as long‑lasting barriers against harmful bacteria and pathogens without changing their appearance or performance. Mare Custos – A subsea robotics company specializing in ROV-based underwater inspection services for offshore energy, ports, and marine infrastructure, using high-precision imaging, PAUT, and NDT to inspect structures in challenging conditions. SmartMed SA – A fast-growing digital health company operating in Tunisia, Algeria, and Morocco, offering an integrated ecosystem that helps patients book appointments (MedPro), enables clinics to digitize workflows and EMRs (MedLink), and supports targeted digital marketing for healthcare and pharma (MedAds). With millions of appointments and users, SmartMed has become a leading e-health platform in North Africa. Sototel – Builds telecommunications networks and services, including fixed, radio, and mobile networks. Sototel focuses on technological innovation and continuous improvement, providing high-value-added digital solutions. SOTUPRIN HGE – Specializes in manufacturing household electrical appliances under the brand HGE and OEM. Expanded from the local market to North Africa, Central Africa, the Middle East, and Europe. Spiraw by Food4Future – Designs and manufactures smart, AI-powered cultivation systems allowing individuals and businesses to grow fresh, highly nutritious food – starting with spirulina – directly at the point of consumption. Combining patented hardware, controlled-environment agriculture, and a connected app with an AI assistant, Spiraw aims to decentralize food production and create a new category at the intersection of agri-tech, consumer health, and smart home ecosystems. WaterSec (Istidama) – A climate-tech startup that uses IoT, AI, and smart sensors to help high consumption facilities (such as industries, hotels, and commercial buildings) monitor water use in real time, detect leaks, and optimize consumption. The company’s digital platform turns raw water data into alerts and actionable insights, making water management more transparent, proactive, and sustainable. Learn more about the SelectUSA Investment Summit at https://www.selectusasummit.us/. Follow live developments from the summit on X at https://x.com/SelectUSA.
Supreme Court temporarily restores access to abortion pill mifepristone through telehealth, mail and pharmacies
The court's order will remain in effect for another week while both sides respond and the court more fully considers the issue.
Global Health & WASH: May 2026 Funding Opportunities (14 new opportunities!)
The May update for Global Health & WASH brings new calls that cluster around three distinct shifts: LMIC research leadership moving from funder encouragement into a hard eligibility constraint, pharmaceutical and corporate-linked funders running structurally independent education and use-inspired research portfolios at substantial scale, and AI adoption shifting decisively from speculative tool to operational capability across health and WASH systems alike. In LMIC Research Leadership as Eligibility, Not Encouragement, Wellcome anchors the dominant signal of the month with three separate major calls that all require or strongly center LMIC leadership in their basic eligibility architecture. Wellcome’s ESIC Hubs (£1.5-£1.9M per hub over 3-5 years) explicitly requires an LMIC-based lead applicant, treating Global South leadership as a design constraint rather than a participation goal. Wellcome’s Infectious Disease Clinical Trial Development Award funds transdisciplinary teams whose lead must be a mid-career or established researcher based at an organization in Africa, South Asia, or Southeast Asia. Wellcome’s larger Infectious Disease Clinical Trial Award (£1M-£8M for optimizing licensed interventions) requires the administering organization to be in eligible LMIC regions and at least 50% of applicants based there. Around Wellcome, the same pattern shows up at smaller scale and across funders: CHINNOVA channels $1M into West and Central African research institutions for climate-health work; IBRO’s Neuroscience Training Grants explicitly tier ceilings by region of residence with Africa receiving the highest amount ($5,000); IHME’s GBD Emerging Researcher Award reserves at least one of its two annual awards for an LMIC researcher; Sidaction’s HIV Cure call funds research teams across France, the Netherlands, and eligible African countries with a minimum two-country collaboration requirement. Taken together, these calls signal a meaningful shift in how research equity is being operationalized — not as encouragement language at the bottom of a call, but as a structural feature of who can lead, where the work must be administered, and what proportion of the team must be regionally rooted. In Pharma-Funded Independent Medical Education and Use-Inspired Research, the lineup this month is unusually deep. Pfizer alone runs four parallel calls under independent education and quality improvement frameworks: a Migraine and Women’s Health RFP (200K x 2-year, $500K pool), Migraine IME ($200K, $1M pool), JAK Inhibitor evidence-based education ($100K), and Maternal Vaccination HCP Education in Saudi Arabia ($75K), plus a separate Pediatric Pneumococcal Surveillance research call in Saudi Arabia ($400K per project). Novo Nordisk Foundation runs four parallel calls of its own at substantial scale: Infectious Diseases Catalyst Grants (DKK 60M pool, up to DKK 7M collaborative), Non-Diabetic Endocrinology Collaborative Grants (DKK 53M pool, DKK 5-10M per project), Pioneer Innovator Grant Health (DKK 1.1M), and Distinguished Innovator Grant Health (DKK 6.8M). LEO Foundation deploys DKK 2-4M per project for dermatology research excellence. Pfizer’s framing across calls deliberately separates the funding from product promotion, emphasizing measurable practice-relevant change and structural distance between scientific outputs and commercial activity. Novo Nordisk’s “use-inspired” hard filter pushes researchers toward a credible translation pathway from mechanism to deployable tool. The pattern: industry-aligned funders are running structurally independent portfolios at meaningful $ that fund implementation evidence, not promotion. In AI as Operational Capability, Not Speculation, several calls this month explicitly treat AI adoption as a near-term operational question with real evidence and governance requirements, rather than a speculative trend to be watched. Wellcome’s ESIC Hubs frames AI as “the accelerator” for evidence synthesis, asking hubs to translate technical innovation into adoption-ready workflows that can match real-world policy timelines. UNICEF Venture Fund’s new Climate Tech for Children’s Health call funds for-profit startups deploying AI, machine learning, and blockchain in low-resource environments, with a strict requirement that solutions must already have a working prototype with promising pilot results. The Water Research Foundation has launched two simultaneous AI calls treating reproducibility, cybersecurity guardrails, and human-in-the-loop deployments as core design constraints rather than nice-to-haves: one on GenAI and Agentic AI in water utilities ($200K), one on alternatives to water shutoffs that explicitly screens for implementation economics evidence. Nordic Innovation’s quantum technology call (NOK 4.5M) extends the same logic into life science and healthcare, demanding consortium-stage projects mature enough to test with real users. TEF-Health offers €300K in subsidized testing infrastructure for European healthcare AI and robotics SMEs. The pattern: funders are converting AI pilots into playbooks, requiring transfer evidence and risk controls before AI can move from experimentation to sector-wide operational practice. For LMIC-based researchers in infectious disease or evidence synthesis, the three Wellcome calls together represent the deepest concentration of LMIC-led research capital in recent memory — pair the Infectious Disease Clinical Trial Development Award (£200K, deadline May 19) as a strategic pipeline feeder into the larger Infectious Disease Clinical Trial Award (£1-£8M, deadline June 2), since the development award functions explicitly as a track into the larger trial scheme. For Nordic researchers, the four Novo Nordisk Foundation calls plus LEO Foundation and Nordic Innovation Quantum represent ~$30M in regional research capital this cycle, all with deadlines clustered in May-August. For WASH practitioners, the three Water Research Foundation calls together (each up to $200K) are a cluster worth reading across — one on AI deployment, one on shutoff alternatives, one rewarding applied innovation — and the strongest applicants will articulate how their work bridges utility operations to policy-relevant evidence. For US-based clinical researchers and educators, the four Pfizer calls plus the APF Portfolio’s 80+ programs form an unusually accessible recurring pipeline; APF’s prohibition on indirect costs is a meaningful structural feature for early-career applicants whose institutions might otherwise absorb significant overhead. Snapshot of New Opportunities Total Estimated Funding Pool: $100 Million+ USD The grants are organized into three categories: Open Calls: Current grant and opportunities with a deadline. Grants are listed by closing date. 39 open opportunities- 14 new! Rolling Applications: current grant and opportunities with rolling applications (but it’s still best to submit as early as possible). 14 rolling opportunities- 1 new opportunity! Long term planning: Grants that have closed their current rounds, but are expected to open new windows. 4 long term opportunities! A quick tip for returning readers: if you want to jump straight to the newest additions, use CTRL F to search for “New!” and navigate quickly to the latest funding opportunities This post is for paid subscribers. This helps support the time and effort it takes to curate and organize these opportunities. Subscribe To keep this accessible to everyone who needs it, we’re happy to offer pay what you can rates. You can find more details here. Open Calls: Migraine Competitive Grant Program: Migraine and Women’s Health (Quality Improvement and/or Research RFP), Pfizer.*Closing soon!* Pfizer, in collaboration with the American Headache Society, is seeking independent quality improvement and research projects that close persistent gaps in migraine care for women across the United States. The funding logic centers on measurable, practice-relevant change: proposals should generate actionable evidence, tools, or system improvements that can be shared and used widely, not just within a single site. Priority areas span menstrual migraine and screening in women’s health settings, the role of hormonal fluctuations across the lifespan, sex-specific risk factors, comorbidities and quality-of-life burden, and disparities in outcomes by race, ethnicity, and socioeconomic status. The call is structured as a two-step competitive process with an initial Letter of Intent, with the strongest concepts expected to translate scientific insight into implementable improvements in diagnosis, management, and equity. Geographies: United States. Who can apply: U.S.-based organizations (not individuals), including professional schools, healthcare institutions, professional organizations, and other entities focused on healthcare improvement. Funding amount: Up to USD $200,000 total over 2 years; total pool USD $500,000. Targeted Sectors / SDGs: Health; Focus areas: migraine, women’s health, quality improvement, clinical research, menstrual migraine, health disparities. Deadline: LOI: May 5, 2026; Full proposal (by invitation): August 28, 2026. Learn more and apply here. This RFP rewards “shareable impact”: the most competitive submissions will pair rigorous methods with a clear plan for system uptake and dissemination beyond the originating institution. ReSSARC: Strengthening the Health Sector and Food Security in the Central African Republic (AID 013381/01/0) Call for Proposals, Italian Agency for Development Cooperation (AICS). *Closing soon!* AICS is seeking a limited set of high-capacity humanitarian partners to deliver an integrated package that stabilizes essential health services while reducing acute malnutrition and strengthening food security resilience in priority areas of the Central African Republic. The funder’s logic is explicitly nexus-based: proposals should meet urgent, life-saving needs while reinforcing local systems, coordination mechanisms, and community-level capacity so results persist beyond the emergency window. AICS emphasizes inclusion and protection outcomes, expecting gender-sensitive design and explicit measures for groups facing compounded vulnerability, including women, children under five, internally displaced people, and people with disabilities. The call also signals a localization pathway, encouraging stronger collaboration with national NGOs and balanced partnerships, alongside clear coordination with existing cluster and humanitarian actors to minimize duplication and improve coverage. Geographies: Central African Republic (Bangui, Ombella-Mpoko, Ouham, Ouham-Pende, Lim-Pende, Lobaye). Who can apply: Non-profit organizations registered with AICS, plus eligible non-profits without an office in Italy that have a pre-existing collaboration agreement with an AICS-listed organization. Funding amount: Total pool EUR €1,800,000; max EUR €800,000 (single applicant) or EUR €1,000,000 (ATS). Targeted Sectors / SDGs: Health; Focus areas: malnutrition prevention and treatment, maternal and child health, community health services, food security and resilience, localization partnerships Deadline: May 5, 2026. Learn more and apply here. This call is structured to reward partners who can link frontline service delivery to system durability and localization, not just short-term coverage gains. Contracts for Innovation in drug and alcohol addiction healthcare, Innovate UK. *Closing soon!* Innovate UK, on behalf of the Office for Life Sciences Addiction Healthcare Goals program, is procuring R&D to accelerate innovations that can improve treatment outcomes, strengthen recovery, and reduce harm and deaths linked to drug and alcohol addiction. The competition is positioned as a market-facing readiness push: selected projects are expected to advance solutions toward later-stage validation, generate evidence of user acceptability and UK market fit, and map credible routes through regulatory and certification requirements. Innovate UK signals a preference for innovations that can be field-tested in relevant UK settings and progressed to TRL 6 or 7, with practical plans for commercialization after contract completion. This structure favors applicants that can execute most work in-house, co-develop with service providers and people with lived experience, and translate technical progress into deployable tools for addiction healthcare delivery. Geographies: United Kingdom. Who can apply: Single organizations of any size (including EU, EEA, or international) leading delivery, with most work and key deliverables carried out in the UK; subcontractors for specialist skills only. Funding amount: GBP £200,000–1.5 million per project (inclusive of VAT); Total pool: GBP £20 million (across two strands). Targeted Sectors / SDGs: Health; Focus areas: Mental Health, Health Systems Strengthening, Research & Development, Technology Access. Deadline: May 6, 2026 (11:00am). Learn more and apply here. This call uses procurement to pull near-market addiction innovations toward operational proof and adoption pathways in UK services.
Opinion | Stop paying doctors to do everyone else's jobs
Letting nurses, pharmacists, and AI handle routine care could make the system cheaper and more efficient.
Binghamton student finds her purpose inside and outside the classroom
Through a Binghamton University public health class and pharmaceutical internship, Camil Ventura ’26 found her calling.
Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic®
/PRNewswire/ - Apotex Inc. ("Apotex" or the "Company"), Canada's largest Canadian‑based global health company, today announced that Health Canada has approved...
Big Pharma throws support behind Ashley Moody in US Senate race
A number of pharmaceutical companies had their drugs removed from a list slated for price reduction negotiations with Medicare officials, thanks to legislation that Moody supported.
Cardinal Health lifts annual profit forecast on strong demand for specialty drugs
Drug distributor Cardinal Health on Thursday raised its 2026 profit forecast range, betting on strong demand for costly specialty medicines and branded drugs at its pharmaceuticals unit.
South Carolina’s measles outbreak is over after sickening nearly 1,000 people
Although measles vaccine uptake was slow at first, public health workers, doctors’ offices and pharmacies administered nearly 82,000 doses from October to March.
Sun Pharma, Eli Lilly Lead Latest Rush of Healthcare M&A
The value of biopharma M&A has more than doubled his year.
Can Collagen Supplements Really Improve Skin and Joint Health? Here's What a Pharmacist Says
Taking collagen supplements can help improve skin and joint health, as it's an important component of skin, and bone tissue.
Sun Pharma signs Definitive Agreement to Acquire Organon
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated co...
Webster's Community Pharmacy celebrates 100 years of business in Altadena
Sheridan College to Host Lecture on Careers in Medical Science Liaison Field
Sheridan College will host a public lecture at 7 p.m. Wednesday, April 29, featuring Jenny McDonald, Ph.D., director and medical science liaison at Novartis Pharmaceuticals Corporation. The event is free and open to the public. The presentation, titled “From Bench to Industry: The Role of Medical Science Liaison,” will take place in Room 153 of […]
UConn Pharmacy Student Honored with USPHS Excellence in Public Health Pharmacy Award
One of the top 10 recipients nationwide, out of 85 total recipients, to receive the United States Public Health Service (USPHS) Excellence in Public Health ...
Health Care Roundup: Market Talk
Find insight on EssilorLuxottica, Hengrui Pharmaceuticals and more in the latest Market Talks covering Health Care.
Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
President Donald Trump on Thursday announced a deal with drugmaker Regeneron to lower the cost of its pharmaceutical products as part of the White House’s signature drug pricing initiative.
JPMorgan shuffles top health care bankers
The changes come as biopharma dealmaking roars back to life.
Watch live: Trump gives remarks on health care affordability
President Trump is hosting an event at the White House on Thursday afternoon centered on health care affordability. Trump is expected to announce a new deal with pharmaceutical company Regeneron, a…
Rowena Dzorvakpor’s dual degree combines health care, business knowledge
The immigrant from Ghana hopes to use her experiences at Carolina to impact insurance groups or pharmaceutical companies.
Rowena Dzorvakpor’s dual degree combines health care, business knowledge
The immigrant from Ghana hopes to use her experiences at Carolina to impact insurance groups or pharmaceutical companies.
Canada’s biotech paradox: strong science, weak scaling
Canada produces a steady stream of biotech startups built on credible academic research. Universities and hospital research centers in Toronto, Montreal, and Vancouver generate discoveries that move quickly into company formation. Early-stage activity is not the constraint. The difficulty tends to surface later, when those companies try to grow.
McLeod Health Holds Ribbon Cutting for New Pharmacy
McLeod Health held a ribbon cutting and open house on April 20, 2026, for its new McLeod Choice Pharmacy. The pharmacy officially opens
Amazon One Medical introduces weight management program with upfront GLP-1 medication costs
The new program combines primary care, pharmacy, and virtual options to treat obesity as a chronic condition—all in one place.
